SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 58.00+3.6%Nov 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: idos who wrote (352)3/16/2011 9:27:42 AM
From: ghmm  Read Replies (2) of 507
 
The official line is that even if they get accelerated approval would need the Phase 3 for full approval. I don't think they are over promising their shot at at accelerated approval. What I am more wondering is if they will need the full Phase 2 data before even starting the Phase 3 which would mean the Phase 3 wouldn't start till 2H '12 (if not later).

The expansion of the Phase 2 study is what has me puzzled. If they really have little to no chance why delay things by expanding the Phase 2? At the Cowen conference Robin said that 125 patients are being added and the results would be pushed back about 4 months (from original end of 11 target).

I was curious if they chance is 0 or something slightly higher :-) so was curious on how the data may compare with what may be expected in that patient population (the company says expected overall survival is about 8 months but I'd like to see some studies).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News